Saturday 17 October 2026
Export XBIO’s income statement to Excel — free account
Xenetic Biosciences, Inc.
XBIO Healthcare Biotechnology
Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 8.89% and free cash flow fell 128.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.98
0.03
−1.49%
Follow XBIO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 4 | 3 | 4 | 3 | 5 |
P/E ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(12.46) | (8.58) | — | (11.65) | (13.09) | (7.15) | (16.08) | (21.77) | (36.53) | (30.91) |
P/S ratio |
0.00 | 0.00 | — | 0.48 | 29.85 | 11.42 | 2.54 | 2.15 | 2.46 | 1.24 |
P/FCF ratio |
0.00 | 11.09 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(31.76) | (21.64) | — | (22.02) | (31.87) | (12.66) | (25.99) | (44.13) | (84.78) | (66.61) |
P/Operating CF |
(8.67) | 3.40 | — | (2.45) | (13.67) | (9.09) | (5.78) | (6.88) | (9.12) | (15.21) |
P/B ratio |
2.48 | 1.15 | — | 0.24 | 1.07 | 0.72 | 0.32 | 0.56 | 1.02 | 0.50 |
Price to Tangible BV |
11.02 | 9.29 | — | 0.52 | 4.39 | 1.45 | 0.99 | 9.91 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | — | (0.60) | 6.06 | (3.32) | (4.47) | (0.94) | 0.45 | (1.03) |
EV/EBITDA |
0.00 | 0.00 | — | 0.53 | 0.00 | 0.67 | 1.14 | 0.53 | 0.00 | 1.08 |
EV/Operating CF |
(4.22) | 8.03 | — | 0.80 | (0.62) | 0.81 | 1.64 | 0.58 | (0.40) | 1.34 |
EV/FCF |
(4.22) | 8.08 | — | 0.80 | (0.62) | 0.81 | 1.64 | 0.58 | (0.40) | 1.34 |
Quick Ratio |
3.81 | 2.88 | 0.40 | 7.33 | 12.30 | 12.84 | 12.20 | 11.10 | 6.89 | 8.14 |
Current Ratio |
4.47 | 3.03 | 0.75 | 7.84 | 13.20 | 13.18 | 12.72 | 11.84 | 7.37 | 8.32 |
Net Debt/EBITDA |
0.09 | 1.58 | 0.09 | 1.08 | 0.83 | 3.19 | 1.96 | 1.99 | 1.47 | 2.78 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.16 | 0.38 | 0.00 | 0.00 | 0.03 | 0.07 | 0.10 | 0.20 | 0.29 | 0.39 |
Operating CF/Net income |
0.15 | (0.42) | 0.89 | 0.35 | 0.39 | 0.84 | 0.71 | 1.00 | 0.71 | 0.85 |
Capex/Depreciation |
(0.03) | (0.39) | 1.42 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Interest Coverage |
(65.01) | (216.29) | (14,552.60) | (59.39) | (110.44) | (57.18) | (40.18) | — | — | — |
| (511.45%) | (23.60%) | (60.31%) | (133.18%) | (74.05%) | (36.89%) | (40.91%) | (35.28%) | (50.13%) | (40.01%) | |
| (307.49%) | (17.91%) | (43.46%) | (100.39%) | (62.74%) | (34.22%) | (37.95%) | (32.65%) | (45.24%) | (35.12%) | |
ROIC |
(245.91%) | (25.63%) | (49.03%) | (117.66%) | (1,266.33%) | (2,389.72%) | (763.68%) | (347.32%) | 0.00% | 0.00% |
Return on Tangible Assets |
(893.94%) | (90.59%) | 1,821.48% | (186.65%) | (95.28%) | (32.63%) | (52.09%) | (47.11%) | (69.56%) | (37.86%) |
Average Days of Receivables |
365.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
1,457.93% | 53.53% | 0.00% | 28,592.40% | 396.29% | 272.55% | 279.50% | 137.59% | 131.52% | 102.99% |
Selling, General and Administrative Expense of Revenue |
223.09% | 91.46% | 0.00% | 27,667.84% | 778.23% | 322.56% | 214.07% | 140.19% | 136.64% | 92.24% |
Intangible Assets out of Total Assets |
0.60 | 0.65 | 0.87 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
70.11% | 23.64% | 0.00% | 4,991.23% | 107.32% | 35.36% | 29.97% | 11.15% | 6.87% | 2.18% |
Graham Net Nets |
0.09 | 0.06 | — | 1.65 | 0.87 | 1.30 | 2.90 | 1.61 | 0.93 | 1.92 |
Graham Number |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(136.38%) | (22.64%) | — | (672.30%) | (82.84%) | (42.31%) | (154.10%) | (77.03%) | (64.41%) | (73.27%) |
Free Cash Flow Yield |
(21.95%) | 9.02% | — | (155.77%) | (32.71%) | (35.72%) | (107.06%) | (75.37%) | (45.78%) | (61.87%) |
Revenue per Share |
48.47 | 105.06 | 0.00 | 0.06 | 0.68 | 1.13 | 1.20 | 1.66 | 1.62 | 1.75 |
Operating CF per Share |
(141.96) | 20.70 | (85.50) | (22.44) | (6.68) | (4.61) | (3.27) | (2.69) | (1.83) | (1.34) |
Capex per Share |
(0.27) | (0.13) | 0.30 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(142.23) | 20.57 | (85.20) | (22.43) | (6.68) | (4.61) | (3.27) | (2.69) | (1.83) | (1.34) |
Cash per Share |
66.47 | 77.56 | 8.44 | 36.35 | 18.03 | 17.75 | 9.21 | 5.88 | 4.00 | 4.63 |
Shareholders Equity per Share |
261.22 | 198.08 | 131.12 | 60.36 | 19.11 | 17.90 | 9.59 | 6.41 | 3.90 | 4.35 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
261.22 | 198.08 | 131.12 | 60.36 | 19.11 | 17.90 | 9.59 | 6.41 | 3.90 | 4.35 |
Free Cash Flow |
(8.80) | 1.48 | (6.44) | (6.40) | (4.27) | (4.74) | (4.65) | (4.11) | (2.82) | (2.29) |
Working Capital |
6.47 | 3.94 | (0.41) | 9.67 | 11.43 | 17.30 | 12.58 | 8.78 | 5.69 | 7.08 |
Capital Expenditures |
(0.02) | (0.01) | 0.02 | 0.00 | — | — | — | — | — | — |
Net Current Asset Value |
3.53 | 1.02 | (3.32) | 6.76 | 11.41 | 17.30 | 12.58 | 8.78 | 5.69 | 7.08 |
EV/EBIT |
0.00 | 0.00 | — | 0.40 | 0.00 | 0.67 | 1.13 | 0.53 | 0.00 | 1.08 |
Capex to Sales |
0.01 | 0.00 | 0.00 | (0.12) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
13.70 | 0.86 | 3.16 | 4,138.63 | 0.00 | 0.00 | 0.00 | — | — | — |
Cash ROIC |
(43.40%) | 7.46% | (61.05%) | (23.19%) | (17.97%) | (12.93%) | (17.37%) | (21.91%) | (23.15%) | (14.97%) |
Accounts Receivable Turnover |
1.84 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.03 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
10,096.66 | 1,839.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.63 | — | — | — | — | — | — | — | — | — |
Average Payables |
1.40 | 0.90 | 0.86 | 0.93 | 0.63 | 0.34 | 0.32 | 0.26 | 0.26 | 0.27 |
Average Assets |
18.94 | 20.07 | 16.80 | 17.99 | 17.36 | 16.50 | 17.27 | 12.66 | 8.75 | 7.63 |
Average Common Equity |
11.39 | 15.23 | 12.10 | 13.56 | 14.71 | 15.30 | 16.02 | 11.72 | 7.90 | 6.70 |
Columns are period end dates